4th Quarter - Report

VIATRIS INC. for VIATRIS INC

Firm
Client
Income
—
Expenses
$630,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs S.344, H.R. 990 - Hatch-Waxman Integrity Act of 2019 Patent Settlements

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
CHRISTOPHER SHERIN —
PETER WALLACE —

Contacted: HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC); White House Office; Office of Management & Budget (OMB); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 990 (116th), S. 344 (116th)

Trade (domestic/foreign) TRD

Trade issues related to generic medicines

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
CHRISTOPHER SHERIN —
PETER WALLACE —

Contacted: Health & Human Services, Dept of (HHS); Natl Economic Council (NEC); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; White House Office; SENATE

Health Issues HCR

Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Generic drug quality and FDA oversight Risk Evaluation and Mitigation Strategies (REMS), H.R. 985 - FAST Generics Act of 2019, S. 340, H.R. 965 - CREATES Act of 2019 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics, S. 2103 - Affordable Insulin Approvals Now Act, H.R. 5444 - Lower Insulin Costs Now Act Medicare reimbursement for biosimilars, shared savings for Part B providers S.2543, Prescription Drug Pricing Reduction Act S. 1416, Affordable Prescriptions for Patients Act S. 1895 Lower Health Care Costs Act of 2019 H.R. 3- Lower Drug Costs Now Act of 2019 H.R. 938 - BLOCKING Act of 2019 H.R. 1499 - The Protecting Consumer Access to Generic Drugs Act of 2019 Part D Formulary Design and Generic Drug Tiering H.R. 4913 - Ensuring Access to Lower-Cost Medicines for Seniors Act S. 64, H.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act H.R. 4455 - BIOSIM Act H.R. 4629 - Star Rating for Biosimilars Act

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
CHRISTOPHER SHERIN —
PETER WALLACE —
ANNE WILSON —

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE; Office of Management & Budget (OMB); White House Office; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC)

Bills named: S. 2543 (116th), H.R. 4913 (116th), S. 340 (116th), H.R. 2375 (116th), H.R. 938 (116th), H.R. 4629 (116th), S. 1895 (116th), H.R. 3 (116th), H.R. 985 (116th), S. 64 (116th), H.R. 5444 (116th), H.R. 965 (116th), S. 1416 (116th), H.R. 4455 (116th), S. 2103 (116th), H.R. 1499 (116th)

Budget/Appropriations BUD

Medicaid Rebate provision of the Bipartisan Budget Act of 2015

Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.

LobbyistCovered position, as disclosed
AKSHAI DATTA —
KATHARINE HAYES —
DAVID MARIN —
MARCIE MCCLINTIC-COATES —
CHRISTOPHER SHERIN —
PETER WALLACE —
ANNE WILSON —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); White House Office; Commerce, Dept of (DOC); Natl Economic Council (NEC)

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
MYLAN HOLDINGS LIMITED United Kingdom United Kingdom 100.0% —
MYLAN NV United Kingdom United Kingdom 100.0% —

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.